ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Trastuzumab deruxtecan is on this study

  • No treatment in the record names it; a reading of the whole record found it given.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 3, 2026, 6:51 AM UTC“In HER2-overexpressing lung cancer”
  • The role rule had no answer: no treatment entry names it.
  • So Trastuzumab deruxtecan's page lists this study under “Testing it”.
2 links1 made here, not in the record2 judgments1 judge (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Made here
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT07662473The Efficacy and Safety ofTrastuzumab Deruxtecan inAdvanced or MetastaticNSCLC With HER2 OverExpressionHunan Province Tumor HospitalPhase 2 · not yet recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.DRUGSTrastuzumab deruxtecanMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · TestedTestedTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · Not givenNot given

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2TrastuzumabClaude Opus 5.5Not givenCurrent
Nov 3Trastuzumab deruxtecanmade hereClaude Opus 5.5TestedCurrent